|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM360883400 |
| 003 |
DE-627 |
| 005 |
20231226083950.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202302801
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1202.xml
|
| 035 |
|
|
|a (DE-627)NLM360883400
|
| 035 |
|
|
|a (NLM)37589156
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Huang, Fanyi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Cellular Membrane-Engineered Nanovesicles as a Three-Stage Booster to Target the Lesion Core
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.11.2023
|
| 500 |
|
|
|a Date Revised 29.11.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a The lesion core is the area with the most serious injury and vigorous repair. Existing nanocarriers are difficult to break through the targeted delivery to the lesion core for precise treatment in the intracellular and extracellular microenvironment. Herein, a cellular membrane-engineered nanovesicle (CMEV) with a hierarchical structure is constructed using the double emulsion-extrusion method by integrating a neutrophil membrane, functional antibody, and gelled drug-loaded core as a three-stage booster to target the lesion core and deliver catestatin (CST), a small therapeutic peptide, for ischemic cardiomyopathy therapy. By coating the neutrophil membrane outside the shell, CMEV is endowed with the function of neutrophil-like migration to achieve the first stage of tissue targeting. Based on the specific anchoring to injured myocardium, a myosin light chain 3 (MLC3) antibody is embedded to fulfill the second stage of CMEV accumulation in the lesion core. The gelled core containing CST-sodium alginate (NaAlg) with a pH-responsive shell is prepared by ionic cross-linking to accomplish the third stage of precise CST administration. Triggered by the microenvironment, NaAlg electrostatically adheres to the lesion core for sustained release, enhancing the efficacy of CST in improving cardiomyocyte apoptosis, excessive fibrosis, macrophage polarization, and angiogenesis. Thus, the "three-stage booster" nanovesicle significantly ameliorates cardiac function and adverse remodeling to treat ischemic cardiomyopathy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a cellular membrane-engineered nanovesicle
|
| 650 |
|
4 |
|a ischemic cardiomyopathy
|
| 650 |
|
4 |
|a lesion core
|
| 650 |
|
4 |
|a targeted delivery
|
| 650 |
|
4 |
|a three-stage booster
|
| 650 |
|
7 |
|a Peptides
|2 NLM
|
| 700 |
1 |
|
|a Du, Yawei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Yanjia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Qiu, Zeping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Zhiyan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fan, Yingze
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, Yunjing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Zhuojin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Ke
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cui, Wenguo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jin, Wei
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 48 vom: 05. Nov., Seite e2302801
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:48
|g day:05
|g month:11
|g pages:e2302801
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202302801
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 48
|b 05
|c 11
|h e2302801
|